Kyrgyzstan pharmaceutical market 2010

1. 2010
KYRGYZSTAN:in prospect

2. Kyrgyzstan Pharmaceutical Market
The access to the pharmaceutical marketplace of any region is always paired with risks,
challenges and political, financial and economical factors specific to each region.
The Government of Kyrgyzstan aims to improve population health, reduce there is a shortage of personnel in remote areas.
the financial burden of seeking care, and improve the quality of health care Maternal mortality rate has increased soon after independence and remains
services. The reforms were initiated in 1996 with the “Manas National at high level. Poverty is an important health determinant; infant mortality
Health Care Reform Program” which outlined the vision of change for 10 rates are 1.8 times higher in the 20% poorest households than in the
years. In 2005, evaluations of the reforms identified substantial progress as wealthiest 20%. A long tradition of childhood immunization with good
well as continuing challenges and remaining tasks. The activities of the coverage of the Expanded Programme on Immunizations (EPI) vaccines has
original Manas reforms are now being carried forward under the “Manas been maintained.
Taalimi National Health Reform Program” for 2006-2010. The new Program
Leading morbidity causes are respiratory (23.8% in 2007) and urogenital
has been approved at the highest government level, and supported by the
system diseases (12.8% in 2007).
international community through a Sector-Wide Approach (SWAp). Both
the first Manas reform plan and its successor focus on a set of Main causes of mortality are cardiovascular diseases (48.3% in 2007), injuries
comprehensive changes in the organization, financing and content of the and poisoning (9.8% in 2007) respiratory diseases (9.4% in 2007), and cancers
health system. (7.9% in 2007).
Health financing reforms eliminated fragmentation which was inherent in Tuberculosis remains an important disease, particularly in prisons
the previously decentralized financing system. This was accomplished (incidence rate over 40 times greater than in general population) where
through the creation of regional purchasing pools (and from 2006, a single multidrug-resistant tuberculosis is a major problem. Syphilis and gonorrhea
national pool) under the Mandatory Health Insurance Fund for allocation of increased until 1997 and decreased since 2000. HIV/AIDS incidence has
resources using output-based strategic purchasing methods, a radical increased, particularly in the southern part of the country along the
change from the previous input-based budgeting process based on opium/heroin trade routes. According to the United Nations Office for
allocations decided centrally. Simultaneously, and in part due to the change Drug Control and Crime Prevention 2001 survey, drug addicts totaled 2% of
of incentives and the Law on Health Care which gave greater autonomy to the total population, mainly males. Waterborne diseases are common due to
providers, hospital downsizing occurred and led to savings on utilities and widespread contamination of water sources.
other fixed costs.
Primary care services have been reorganized in Family Group Practices
(FGPs), which by 2004 had enrolled approximately 98.5% of the population. Kyrgyzstan:in prospect is available
An outpatient drug benefit has been introduced to improve access to
medicines for primary care management of conditions such as hypertension
at Euros 145.00
and to reduce unnecessary hospitalizations. Despite continuous increases in To know more about our report or to discuss this topic further
funding for primary health care, salaries for healthcare staff remain low and please do not hesitate to contact us
Tel/Fax: +38 044 206 17 17/18
e-mail: office@smd.net.ua

3. Kyrgyzstan:in prospect
EECCA: Region Features
Economic Development
Pharmaceutical Market: Executive Summary
Pharmaceutical Market: Main Features
Pharmaceutical Market: Structure
Per capita expenses
Kyrgyzstan
Country profile
Economy
Healthcare system features
Healthcare system funding
Financial flows within the national health system
Trends in healthcare expenditure, 2003-2007
Structure of total healthcare expenditure 2001-2009
Kyrgyzstan: Pharma Market
Main features
Weighted average cost of a pack by segments
ATC 1 share. Total market, USD
ATC 1 share. Total market, Units
ATC 1 share. Rx segment, USD
ATC 1 share. Rx segment, Units
DISCLAIMER ATC 1 share. OTC segment, USD
All information contained in this publication
has been researched and compiled from sources ATC 1 share. OTC segment, Units
believed to be accurate and reliable at the time Leading corporations. Total market, USD
of publishing. However, SMD accepts no
liability whatsoever for any loss or damage Leading corporations. Total market, Units
resulting from errors, inaccuracies or omissions Leading corporations. Rx segment, USD
affecting any part of the publication. All
information is provided without warranty, and
Leading corporations. Rx segment, Units
SMD makes no representation of warranty of Leading corporations. OTC segment, USD
any kind as to the accuracy or completeness of
any information hereto contained.
Leading corporations. OTC segment, Units
Kyrgyzstan: Forecast for 2011-2013
Kyrgyzstan:in prospect Pharma market, USD
© 2011 SMD
All information contained in this publication is copyrighted in the name of SMD (Support in Market Development), and as such no part of
this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means
graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means,
without the express written consent of the publisher.

4. SMD (Support in Market Development) - is a leading provider of market research,
sales management and forecasting services to the pharmaceutical industry.
Researches of:
· Pharmaceutics establishments' purchase and sale audit
· Hospital establishments' purchase audit
· Second distribution audit Ukraine, 03680
· Import medicine analyses Bojenko str., 86i, Kiev
· Doctor prescription analyses Tel/Fax: +38 044 206 17 17/18
· Ad Hoc research e-mail: office@smd.net.ua
· Analytical services http://www.smd.net.ua
Kyrgyzstan:in prospect
April 2011